Tango Therapeutics, Inc.
TNGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,591.6% | -41% | 31% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99% | 80.4% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 30.5% | -1,200.7% | -777.2% | -978.6% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 29.5% | -1,221.4% | -739.5% | -915% |
| EPS Diluted | 0.143 | -0.35 | -0.36 | -0.34 |
| % Growth | 140.9% | 2.8% | -5.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |